LEO Pharma agreed to pay Britain-based Astrazeneca $115 million in upfront payment and another $1 billion in milestones for the rights to tralokinumab, an experimental mid-stage drug used to treat atopic dermatitis. In the deal, Astrazeneca will retain the rights to develop the drug for treatment of severe asthma.
Astrazeneca also terminated a licensing deal with Canadian Valeant Pharmaceuticals for brodalumab, an experimental psoriasis drug, and sold the European rights to LEO Pharma for an undisclosed amount.
The deals are expected to close in late 2016.
More articles on the drug market:
GSK’s malaria vaccine shows diminished efficacy after 7 years
Drugmakers target vaccines for a new market: pregnant women
German researchers test ‘universal cancer vaccine’
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
